Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients

Patients with chronic lymphocytic leukemia (CLL) relapsing on ibrutinib are often treated with the Bcl-2 inhibitor venetoclax. However, the transition from one agent to another poses some clinical challenges due to disease flares sometimes occurring right after ibrutinib interruption. Here, we descr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrarini, Isacco, Gandini, Francesca, Zapparoli, Ettore, Rigo, Antonella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028984/
https://www.ncbi.nlm.nih.gov/pubmed/35448201
http://dx.doi.org/10.3390/curroncol29040227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028984/
https://www.ncbi.nlm.nih.gov/pubmed/35448201
http://dx.doi.org/10.3390/curroncol29040227

Ejemplares similares